Enliven Therapeutics, - Common Stock (id:7856 ELVN)
24.54 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 10:09:32 AM)
Exchange closed, opens in 23 hours 20 minutes
-3.76 USD (-3.76%)
1.36 USD (1.36%)
-13.01 USD (-13.01%)
0.82 USD (0.82%)
112.84 USD (112.84%)
75.29 USD (75.29%)
About Enliven Therapeutics, - Common Stock
Market Capitalization 1.22B
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.
| Headquarters (address) |
6200 Lookout Road Boulder 80301 CO United States |
| Phone | 720 647 8519 |
| Website | https://www.enliventherapeutics.com |
| Employees | 52 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | ELVN |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 9.80 - 30.03 |
| Market Capitalization | 1.22B |
| P/E trailing | -12.21 |
| P/E forward | -10.51 |
| Price/Book | 0.004 |
| EPS | -1.93 |
| EPS United States (ID:6, base:3402) | 24.22 |